Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.

Saved in:
Bibliographic Details
Title: Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Authors: Trapani D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Jin Q; Data Science, Dana-Farber Cancer Institute, Boston, MA., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Rugo HS; University of California at San Francisco, San Francisco, CA., Reeder-Hayes KE; University of North Carolina, Lineberger Comprehensive Cancer Institute, Chapel Hill, NC., Traina T; Memorial Sloan Kettering Cancer Center, New York, NY., Abdou Y; University of North Carolina, Lineberger Comprehensive Cancer Institute, Chapel Hill, NC., Falkson C; University of Alabama, Birmingham, AL., Abramson V; Vanderbilt University, Nashville, TN., Ligibel J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Chen W; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Come S; Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA., Nohria A; Harvard Medical School, Boston, MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA., Ryabin N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Tayob N; Harvard Medical School, Boston, MA; Data Science, Dana-Farber Cancer Institute, Boston, MA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Mayer EL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: erica_mayer@dfci.harvard.edu.
Source: Clinical breast cancer [Clin Breast Cancer] 2025 Jun; Vol. 25 (4), pp. e419-e430.e5. Date of Electronic Publication: 2024 Dec 31.
Publication Type: Comparative Study; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0666
DOI:10.1016/j.clbc.2024.12.018